- In patients with acute myeloid leukemia (AML) who received standard chemotherapy, reduced weight at the time of hematopoietic stem cell transplantation (HSCT) was associated with inferior survival outcomes.
Why this matters
- This is one of the largest studies regarding changes in weight and post-HSCT outcomes in this setting.
- Study to investigate associations between BMI change after intensive chemotherapy and post-HSCT survival outcomes in 184 patients with newly diagnosed AML.
- When stratified by BMI at transplant minus BMI at diagnosis (d-BMI):
- 13.1% were d-BMI 2.
- 70.6% were d-BMI −2 to +2 kg/m2.
- 16.3% were d-BMI >+2 kg/m2.
- Funding: Yokohama Cooperative Study Group for Hematology.
- Graft-vs-host DFS (GRFS) by d-BMI category (P=.0067):
- 16.1% (95% CI, 5.1%-31.4%) in patients with d-BMI 2.
- 45.4% (95% CI, 36.4%-53.7%) in patients with d-BMI −2 to +2 kg/m2.
- 41.7% (95% CI, 22.2%-60.1%) in patients with d-BMI >+2 kg/m2.
- In multivariate analysis:
- Significant correlation between d-BMI 2 and inferior OS vs weight maintenance group: HR, 1.78; 95% CI, 1.02-3.14; P=.045.
- Significant association between d-BMI 2 and inferior GRFS: HR, 2.34; 95% CI, 1.16-4.35; P=.007.
- Limited sample size.